Detalhe da pesquisa
1.
Post COVID-19 condition imposes significant burden in patients with advanced chronic kidney disease: A nested case-control study.
Int J Infect Dis
; 142: 106990, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38428480
2.
Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.
Viruses
; 16(1)2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38257814
3.
The Time-Dependent Association of Torque Teno Virus Load with the Level of SARS-CoV-2 S1 IgG Antibodies Following COVID-19 Vaccination in Kidney Transplant Recipients.
Viruses
; 15(11)2023 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-38005867
4.
Impact of immunosuppressive treatment and type of SARS-CoV-2 vaccine on antibody levels after three vaccinations in patients with chronic kidney disease or kidney replacement therapy.
Clin Kidney J
; 16(3): 528-540, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36865021
5.
Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
Lancet Infect Dis
; 23(3): 307-319, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36354032
6.
Association of obesity with 3-month mortality in kidney failure patients with COVID-19.
Clin Kidney J
; 15(7): 1348-1360, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35747092
7.
SARS-CoV-2 Spike-specific IFN-γ T-cell Response After COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
Transplant Direct
; 8(11): e1387, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36284929
8.
The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant.
Transplantation
; 106(4): 821-834, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34753894
9.
Difference in sensitivity between SARS-CoV-2-specific T cell assays in patients with underlying conditions.
J Clin Invest
; 131(24)2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34907916